Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS with PIPAC for Peritoneal Metastasis
NCT05431907Phase 2Terminated
- Sponsor
- Enlivex Therapeutics
- Start
- Jun 2022
- Primary completion
- Mar 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Allocetra in peritoneal metastasis (PM), sponsored by Enlivex Therapeutics. Started Jun 2022; status: terminated.
02
Drugs
Allocetra
03
Conditions
peritoneal metastasis (PM)
Beyond the preview
Go deeper on NCT05431907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431907.